FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

Related Articles

Research

Research Alert: CFRA Keeps Hold Rating On Shares Of Baxter International Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our price target to $19 from $23, using a forward P/E of 9.5x our 2027 EPS view, a sizable discount to BAX's 10-year historical forward average. We slightly adjust our 2026 EPS estimate to $2.00 from $1.96 and maintain our 2027 EPS estimate at $1.99. Baxter delivered mixed Q1 results that reflected ongoing operational challenges despite management's transformation efforts, in our view. Sales of $2.7 billion rose 3% on a reported basis but declined 1% organically. EPS was $0.36, a 35% Y/Y decrease from the prior year, reflecting significant headwinds from tariffs, higher manufacturing costs, and an unfavorable comparison with Q1 2025. We think that BAX could be in the early stages of a turnaround focused on stabilizing the business and strengthening the balance sheet. Yet, we see the potential for a slowdown in U.S. hospital capital spending due to macroeconomic uncertainties along with continued softer demand for inhaled anesthesia products globally as important risks.

$BAX
Research

Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Rocket Lab Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price to $100 from $80, applying an EV/sales multiple of 45.8x to our 2027 estimate. This multiple is a slight premium to its five-year historical average multiple at 43.1x. We raise our 2026 loss per share estimate to -$0.11 from -$0.18 and cut 2027's EPS estimate to $0.05 from $0.14. Despite the Stage 1 tank setback, Neutron development showed meaningful progress. Multiple critical subsystems passed qualification during the quarter, including the Hungry Hippo fairing, thrust structure, and Stage 2. Flight hardware is now arriving at the Wallops launch site for final integration and testing. First launch is now targeted for Q4 2026. RKLB is not waiting for the first flight to build subsequent vehicles. Management noted that production of additional Neutron tail numbers is already underway, which means follow-on flights will not be delayed by the same duration as the first launch.

$RKLB
Research

Research Alert: CFRA Reiterates Sell Rating On Shares Of Udr, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We think UDR will be an underperformer versus the S&P 500, and the trust's fundamental outlook is low-single digit growth at best. We keep our $34 target using a forward P/FFO of 13.3x below peer group given its high concentration in Sun Belt markets. We keep our 2026 FFO estimate at $2.55 and lower 2027's by $0.01 to $2.60 on revenue projections of $1.72B and $1.77B, respectively. We think this puts added pressure on UDR's ability to raise rental rates, especially for new leases where incentives like free months are still needed. Renewal leasing also faces some limitations to how much UDR can raise rents as tenants can relocate to competitor housing. Cash NOI outlook is not promising. An important metric to monitor is cash NOI, which takes into account rental revenue less operating expenses that have risen at a faster pace (higher labor, insurance, and property taxes). UDR's 2026 targets are same-store revenue growth of 0.25% to 2.25%, expense growth of 3.00% to 4.50%, and cash NOI growth of -1.00% to 1.25%.

$UDR